[
  {
    "ts": "2025-10-27T11:30:00+00:00",
    "headline": "Intellia Therapeutics Provides Update on MAGNITUDE Clinical Trials of Nexiguran Ziclumeran (nex-z)",
    "summary": "Conference call today at 8:30 a.m. ETCAMBRIDGE, Mass., Oct. 27, 2025 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading clinical-stage gene editing company focused on revolutionizing medicine with CRISPR-based therapies, today announced that the company has temporarily paused patient dosing and screening for its MAGNITUDE and MAGNITUDE-2 Phase 3 clinical trials of nex-z for patients with transthyretin amyloidosis with cardiomyopathy (ATTR-CM) and polyneuropathy (ATTR-PN), r",
    "url": "https://finance.yahoo.com/news/intellia-therapeutics-provides-magnitude-clinical-113000850.html",
    "source": "GlobeNewswire",
    "provider": "yfinance",
    "raw": {
      "id": "639e3445-eb2c-3098-b8d6-c69c9ec57f0e",
      "content": {
        "id": "639e3445-eb2c-3098-b8d6-c69c9ec57f0e",
        "contentType": "STORY",
        "title": "Intellia Therapeutics Provides Update on MAGNITUDE Clinical Trials of Nexiguran Ziclumeran (nex-z)",
        "description": "",
        "summary": "Conference call today at 8:30 a.m. ETCAMBRIDGE, Mass., Oct. 27, 2025 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading clinical-stage gene editing company focused on revolutionizing medicine with CRISPR-based therapies, today announced that the company has temporarily paused patient dosing and screening for its MAGNITUDE and MAGNITUDE-2 Phase 3 clinical trials of nex-z for patients with transthyretin amyloidosis with cardiomyopathy (ATTR-CM) and polyneuropathy (ATTR-PN), r",
        "pubDate": "2025-10-27T11:30:00Z",
        "displayTime": "2025-10-27T11:30:00Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/globenewswire.com/cc90f97da0ab89e42cba6497d0363207",
          "originalWidth": 699,
          "originalHeight": 350,
          "caption": "",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/riqI5T.7geNxe1INtuNDWA--~B/aD0zNTA7dz02OTk7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/globenewswire.com/cc90f97da0ab89e42cba6497d0363207.cf.webp",
              "width": 699,
              "height": 350,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/N3lOy8p3R2lvpjEyEDLcdw--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/globenewswire.com/cc90f97da0ab89e42cba6497d0363207.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "GlobeNewswire",
          "url": "https://www.globenewswire.com/"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/news/intellia-therapeutics-provides-magnitude-clinical-113000850.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/intellia-therapeutics-provides-magnitude-clinical-113000850.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "NTLA"
            },
            {
              "symbol": "REGN"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2025-10-27T11:00:00+00:00",
    "headline": "OncoNano Medicine Presents First-in-Human Data Demonstrating Safety and Early Signs of Clinical Activity of ONM-501, a Dual-Acting STING Agonist, at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics",
    "summary": "DALLAS, October 27, 2025--OncoNano Medicine, Inc. (\"OncoNano\") announced encouraging first-in-human results from Part 1 of its Phase 1 ON-5001 trial evaluating ONM-501, a dual-acting STING agonist, as monotherapy and in combination with Libtayo® (cemiplimab), Regeneron’s PD-1 inhibitor, in patients with advanced solid tumors and lymphomas. The findings were shared during a poster presentation at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics in Boston, M",
    "url": "https://finance.yahoo.com/news/onconano-medicine-presents-first-human-110000651.html",
    "source": "Business Wire",
    "provider": "yfinance",
    "raw": {
      "id": "fcae8967-e84c-35d9-8d5e-0e0a1d7651d5",
      "content": {
        "id": "fcae8967-e84c-35d9-8d5e-0e0a1d7651d5",
        "contentType": "STORY",
        "title": "OncoNano Medicine Presents First-in-Human Data Demonstrating Safety and Early Signs of Clinical Activity of ONM-501, a Dual-Acting STING Agonist, at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics",
        "description": "",
        "summary": "DALLAS, October 27, 2025--OncoNano Medicine, Inc. (\"OncoNano\") announced encouraging first-in-human results from Part 1 of its Phase 1 ON-5001 trial evaluating ONM-501, a dual-acting STING agonist, as monotherapy and in combination with Libtayo® (cemiplimab), Regeneron’s PD-1 inhibitor, in patients with advanced solid tumors and lymphomas. The findings were shared during a poster presentation at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics in Boston, M",
        "pubDate": "2025-10-27T11:00:00Z",
        "displayTime": "2025-10-27T11:00:00Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/business-wire.com/806200fd070a68002d4586edf6e189f3",
          "originalWidth": 480,
          "originalHeight": 480,
          "caption": "",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/mJ8mnaUrUEgTc86FnyYZMQ--~B/aD00ODA7dz00ODA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/business-wire.com/806200fd070a68002d4586edf6e189f3.cf.webp",
              "width": 480,
              "height": 480,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/qzUMi6pJRJvABupk2z.W1g--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/business-wire.com/806200fd070a68002d4586edf6e189f3.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "Business Wire",
          "url": "http://www.businesswire.com/"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/news/onconano-medicine-presents-first-human-110000651.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/onconano-medicine-presents-first-human-110000651.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "REGN"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2025-10-27T04:17:16+00:00",
    "headline": "A Look at Regeneron Pharmaceuticals’s Valuation Following Key European Regulatory Win for Libtayo",
    "summary": "Regeneron Pharmaceuticals (REGN) just moved a step closer to expanding its cancer therapy portfolio in Europe after the European Medicines Agency’s committee issued a positive opinion for Libtayo as an adjuvant treatment for certain skin cancer patients. See our latest analysis for Regeneron Pharmaceuticals. This regulatory progress adds to a busy stretch for Regeneron, which recently presented at the ESMO Congress and has continued ramping up share repurchases according to major...",
    "url": "https://finance.yahoo.com/news/look-regeneron-pharmaceuticals-valuation-following-041716960.html",
    "source": "Simply Wall St.",
    "provider": "yfinance",
    "raw": {
      "id": "3e120ca5-d95a-3f39-b14f-6ef5cfc9ec14",
      "content": {
        "id": "3e120ca5-d95a-3f39-b14f-6ef5cfc9ec14",
        "contentType": "STORY",
        "title": "A Look at Regeneron Pharmaceuticals’s Valuation Following Key European Regulatory Win for Libtayo",
        "description": "",
        "summary": "Regeneron Pharmaceuticals (REGN) just moved a step closer to expanding its cancer therapy portfolio in Europe after the European Medicines Agency’s committee issued a positive opinion for Libtayo as an adjuvant treatment for certain skin cancer patients. See our latest analysis for Regeneron Pharmaceuticals. This regulatory progress adds to a busy stretch for Regeneron, which recently presented at the ESMO Congress and has continued ramping up share repurchases according to major...",
        "pubDate": "2025-10-27T04:17:16Z",
        "displayTime": "2025-10-27T04:17:16Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/simply_wall_st__316/a52f4d4b48157c0b8b51190845e3ba14",
          "originalWidth": 1194,
          "originalHeight": 432,
          "caption": "",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/w30LARiR1Z35GusfaFi.2g--~B/aD00MzI7dz0xMTk0O2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/simply_wall_st__316/a52f4d4b48157c0b8b51190845e3ba14.cf.webp",
              "width": 1194,
              "height": 432,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/3eDp_RSETU8kXm3usDK_gQ--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/simply_wall_st__316/a52f4d4b48157c0b8b51190845e3ba14.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "Simply Wall St.",
          "url": "https://simplywall.st/"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/news/look-regeneron-pharmaceuticals-valuation-following-041716960.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/look-regeneron-pharmaceuticals-valuation-following-041716960.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "REGN"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2025-10-27T03:13:26+00:00",
    "headline": "Regeneron Earnings: What To Look For From REGN",
    "summary": "Biotech company Regeneron (NASDAQ:REGN) will be announcing earnings results this Tuesday before market open. Here’s what you need to know.",
    "url": "https://finance.yahoo.com/news/regeneron-earnings-look-regn-031326168.html",
    "source": "StockStory",
    "provider": "yfinance",
    "raw": {
      "id": "09aae72c-a1ac-310a-8c96-2ea627dea87c",
      "content": {
        "id": "09aae72c-a1ac-310a-8c96-2ea627dea87c",
        "contentType": "STORY",
        "title": "Regeneron Earnings: What To Look For From REGN",
        "description": "",
        "summary": "Biotech company Regeneron (NASDAQ:REGN) will be announcing earnings results this Tuesday before market open. Here’s what you need to know.",
        "pubDate": "2025-10-27T03:13:26Z",
        "displayTime": "2025-10-27T03:13:26Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/stockstory_922/863b7649ab1334021118a8518d7e40cd",
          "originalWidth": 1400,
          "originalHeight": 700,
          "caption": "REGN Cover Image",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/E5YeVaDzgHlFxvDwMx9gpg--~B/aD03MDA7dz0xNDAwO2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/stockstory_922/863b7649ab1334021118a8518d7e40cd.cf.webp",
              "width": 1400,
              "height": 700,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/6HLp77Q1Eazwpb8zaGf6Xg--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/stockstory_922/863b7649ab1334021118a8518d7e40cd.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "StockStory",
          "url": "https://stockstory.org/"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/news/regeneron-earnings-look-regn-031326168.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/regeneron-earnings-look-regn-031326168.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "REGN"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  }
]